APPLIED DNA SCIENCES INC (APDN)
US03815U3005 - Common Stock
We assign a fundamental rating of 2 out of 10 to APDN. APDN was compared to 59 industry peers in the Life Sciences Tools & Services industry. APDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APDN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year APDN has reported negative net income.
In the past year APDN has reported a negative cash flow from operations.
APDN had negative earnings in each of the past 5 years.
In the past 5 years APDN always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -73.49%, APDN is doing worse than 94.92% of the companies in the same industry.
With a Return On Equity value of -172.13%, APDN is not doing good in the industry: 88.14% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.49% | ||
| ROE | -172.13% | ||
| ROIC | N/A |
ROA(3y)-69.86%
ROA(5y)-115.07%
ROE(3y)-131.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APDN has a Gross Margin of 37.66%. This is in the lower half of the industry: APDN underperforms 62.71% of its industry peers.
In the last couple of years the Gross Margin of APDN has declined.
APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.92%
GM growth 5Y-9.77%
2. Health
2.1 Basic Checks
APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APDN has more shares outstanding
Compared to 5 years ago, APDN has more shares outstanding
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -45.63, we must say that APDN is in the distress zone and has some risk of bankruptcy.
APDN has a worse Altman-Z score (-45.63) than 96.61% of its industry peers.
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.63 |
ROIC/WACCN/A
WACC12.12%
2.3 Liquidity
APDN has a Current Ratio of 1.77. This is a normal value and indicates that APDN is financially healthy and should not expect problems in meeting its short term obligations.
APDN's Current ratio of 1.77 is on the low side compared to the rest of the industry. APDN is outperformed by 69.49% of its industry peers.
APDN has a Quick Ratio of 1.63. This is a normal value and indicates that APDN is financially healthy and should not expect problems in meeting its short term obligations.
APDN's Quick ratio of 1.63 is on the low side compared to the rest of the industry. APDN is outperformed by 61.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
APDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.40%, which is quite good.
APDN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -53.29%.
APDN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.94% yearly.
EPS 1Y (TTM)19.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q70%
Revenue 1Y (TTM)-53.29%
Revenue growth 3Y90.62%
Revenue growth 5Y27.94%
Revenue growth Q2Q-83.06%
3.2 Future
The Earnings Per Share is expected to grow by 13.10% on average over the next years. This is quite good.
The Revenue is expected to decrease by -24.33% on average over the next years. This is quite bad
EPS Next Y11.6%
EPS Next 2Y13.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-64.83%
Revenue Next 2Y-24.33%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APDN's earnings are expected to grow with 13.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for APDN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APPLIED DNA SCIENCES INC
NASDAQ:APDN (4/19/2024, 2:58:47 PM)
0.3416
+0 (+1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.80M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.49% | ||
| ROE | -172.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)19.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-53.29%
Revenue growth 3Y90.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y